IT201800009282A1 - Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi - Google Patents

Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi Download PDF

Info

Publication number
IT201800009282A1
IT201800009282A1 IT102018000009282A IT201800009282A IT201800009282A1 IT 201800009282 A1 IT201800009282 A1 IT 201800009282A1 IT 102018000009282 A IT102018000009282 A IT 102018000009282A IT 201800009282 A IT201800009282 A IT 201800009282A IT 201800009282 A1 IT201800009282 A1 IT 201800009282A1
Authority
IT
Italy
Prior art keywords
met
human
domain
amino acid
antibody fragment
Prior art date
Application number
IT102018000009282A
Other languages
English (en)
Italian (it)
Inventor
Elisa Vigna
Cristina Basilico
Tiziana Crepaldi
Paolo Maria Comoglio
Original Assignee
Metis Prec Medicine Sb Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metis Prec Medicine Sb Srl filed Critical Metis Prec Medicine Sb Srl
Priority to IT102018000009282A priority Critical patent/IT201800009282A1/it
Priority to KR1020257016475A priority patent/KR20250078600A/ko
Priority to EP19808675.3A priority patent/EP3864050B1/en
Priority to CN202411779087.7A priority patent/CN119587692A/zh
Priority to ES19808675T priority patent/ES2938714T3/es
Priority to KR1020217013513A priority patent/KR102814490B1/ko
Priority to CA3115582A priority patent/CA3115582A1/en
Priority to SG11202103575RA priority patent/SG11202103575RA/en
Priority to DK19808675.3T priority patent/DK3864050T5/da
Priority to JP2021518891A priority patent/JP7371093B2/ja
Priority to CN201980080611.2A priority patent/CN113330032B/zh
Priority to RS20230107A priority patent/RS63960B1/sr
Priority to PCT/EP2019/077116 priority patent/WO2020074459A1/en
Priority to FIEP19808675.3T priority patent/FI3864050T3/fi
Priority to SM20230053T priority patent/SMT202300053T1/it
Priority to IL282033A priority patent/IL282033B2/en
Priority to PT198086753T priority patent/PT3864050T/pt
Priority to LTEPPCT/EP2019/077116T priority patent/LT3864050T/lt
Priority to US17/283,482 priority patent/US12209129B2/en
Priority to PL19808675.3T priority patent/PL3864050T3/pl
Priority to EP22206743.1A priority patent/EP4194469A1/en
Priority to HUE19808675A priority patent/HUE060843T2/hu
Priority to HRP20230154TT priority patent/HRP20230154T1/hr
Priority to AU2019358417A priority patent/AU2019358417B2/en
Priority to SI201930456T priority patent/SI3864050T1/sl
Publication of IT201800009282A1 publication Critical patent/IT201800009282A1/it
Priority to CY20231100073T priority patent/CY1125831T1/el
Priority to US18/973,463 priority patent/US20250101115A1/en
Priority to AU2026201438A priority patent/AU2026201438A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT102018000009282A 2018-10-09 2018-10-09 Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi IT201800009282A1 (it)

Priority Applications (28)

Application Number Priority Date Filing Date Title
IT102018000009282A IT201800009282A1 (it) 2018-10-09 2018-10-09 Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
SM20230053T SMT202300053T1 (it) 2018-10-09 2019-10-07 Fab-fc anti-met per il trattamento di un tumore e/o metastasi
FIEP19808675.3T FI3864050T3 (fi) 2018-10-09 2019-10-07 Anti-met-fab-fc kasvaimen ja/tai metastaasin hoitamiseksi
CN202411779087.7A CN119587692A (zh) 2018-10-09 2019-10-07 用于治疗肿瘤和/或转移的抗Met Fab-Fc
ES19808675T ES2938714T3 (es) 2018-10-09 2019-10-07 Fab-Fc anti-Met para el tratamiento de un tumor y/o metástasis
IL282033A IL282033B2 (en) 2018-10-09 2019-10-07 Anti-met fab-fc for the treatment of tumors and/or metastases
CA3115582A CA3115582A1 (en) 2018-10-09 2019-10-07 Anti-met fab-fc for the treatment of a tumor and/or metastasis
SG11202103575RA SG11202103575RA (en) 2018-10-09 2019-10-07 Anti-met fab-fc for the treatment of a tumor and/or metastasis
DK19808675.3T DK3864050T5 (da) 2018-10-09 2019-10-07 Anti-met-fab-fc til behandling af en tumor og/eller metastase
JP2021518891A JP7371093B2 (ja) 2018-10-09 2019-10-07 腫瘍および／または転移の治療のための抗－ｍｅｔ ｆａｂ－ｆｃ
CN201980080611.2A CN113330032B (zh) 2018-10-09 2019-10-07 用于治疗肿瘤和/或转移的抗Met Fab-Fc
RS20230107A RS63960B1 (sr) 2018-10-09 2019-10-07 Anti-met fab-fc za lečenje tumora i/ili metastaza
PCT/EP2019/077116 WO2020074459A1 (en) 2018-10-09 2019-10-07 Anti-met fab-fc for the treatment of a tumor and/or metastasis
KR1020257016475A KR20250078600A (ko) 2018-10-09 2019-10-07 종양 및/또는 전이의 치료를 위한 항-Met Fab-Fc
SI201930456T SI3864050T1 (sl) 2018-10-09 2019-10-07 Anti-Met Fab-Fc za zdravljenje tumorja in/ali metastaze
KR1020217013513A KR102814490B1 (ko) 2018-10-09 2019-10-07 종양 및/또는 전이의 치료를 위한 항-Met Fab-Fc
PT198086753T PT3864050T (pt) 2018-10-09 2019-10-07 Fab-fc anti-met para o tratamento de um tumor e/ou metástase
LTEPPCT/EP2019/077116T LT3864050T (lt) 2018-10-09 2019-10-07 Fab-fc prieš met, skirtas auglio ir (arba) metastazių gydymui
US17/283,482 US12209129B2 (en) 2018-10-09 2019-10-07 Anti-Met fab-Fc for the treatment of a tumor and/or metastasis
PL19808675.3T PL3864050T3 (pl) 2018-10-09 2019-10-07 FAB-FC ANTY-MET do leczenia nowotworu i/lub przerzutu
EP22206743.1A EP4194469A1 (en) 2018-10-09 2019-10-07 Anti-met fab-fc for the treatment of a tumor and/or metastasis
HUE19808675A HUE060843T2 (hu) 2018-10-09 2019-10-07 Anti-Met Fab-Fc tumor és/vagy metasztázis kezelésére
HRP20230154TT HRP20230154T1 (hr) 2018-10-09 2019-10-07 Anti-met fab-fc za liječenje tumora i/ili metastaza
AU2019358417A AU2019358417B2 (en) 2018-10-09 2019-10-07 Anti-Met Fab-Fc for the treatment of a tumor and/or metastasis
EP19808675.3A EP3864050B1 (en) 2018-10-09 2019-10-07 Anti-met fab-fc for the treatment of a tumor and/or metastasis
CY20231100073T CY1125831T1 (el) 2018-10-09 2023-02-09 Αντι-met fab-fc για τη θεραπεια ενος ογκου ή/και μεταστασης
US18/973,463 US20250101115A1 (en) 2018-10-09 2024-12-09 Anti-met fab-fc for the treatment of a tumor and/or metastasis
AU2026201438A AU2026201438A1 (en) 2018-10-09 2026-02-26 Anti-met fab-fc for the treatment of a tumor and/or metastasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102018000009282A IT201800009282A1 (it) 2018-10-09 2018-10-09 Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi

Publications (1)

Publication Number Publication Date
IT201800009282A1 true IT201800009282A1 (it) 2020-04-09

Family

ID=65010823

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102018000009282A IT201800009282A1 (it) 2018-10-09 2018-10-09 Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi

Country Status (23)

Country Link
US (2) US12209129B2 (https=)
EP (2) EP3864050B1 (https=)
JP (1) JP7371093B2 (https=)
KR (2) KR20250078600A (https=)
CN (2) CN119587692A (https=)
AU (2) AU2019358417B2 (https=)
CA (1) CA3115582A1 (https=)
CY (1) CY1125831T1 (https=)
DK (1) DK3864050T5 (https=)
ES (1) ES2938714T3 (https=)
FI (1) FI3864050T3 (https=)
HR (1) HRP20230154T1 (https=)
HU (1) HUE060843T2 (https=)
IL (1) IL282033B2 (https=)
IT (1) IT201800009282A1 (https=)
LT (1) LT3864050T (https=)
PL (1) PL3864050T3 (https=)
PT (1) PT3864050T (https=)
RS (1) RS63960B1 (https=)
SG (1) SG11202103575RA (https=)
SI (1) SI3864050T1 (https=)
SM (1) SMT202300053T1 (https=)
WO (1) WO2020074459A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260019463A (ko) 2023-06-01 2026-02-10 피에르 파브르 메디카먼트 종양 및 전이의 치료를 위한 침묵화된 항체 기반의 항-met 구조물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063816A2 (en) * 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
WO2007090807A1 (en) 2006-02-06 2007-08-16 Metheresis Translational Research S.A. Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
WO2013033008A2 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
WO2014108829A1 (en) * 2013-01-09 2014-07-17 Metheresis Translational Research S.A. New antibody fragments, compositions and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2547248T3 (es) * 2006-04-28 2015-10-02 Delenex Therapeutics Ag Anticuerpos que se unen al dominio extracelular del receptor Tirosina cinasa ALK
NZ591087A (en) * 2008-10-01 2012-08-31 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
EP2376109B1 (en) * 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof
MX2011010265A (es) * 2009-04-01 2011-10-11 Genentech Inc Anticuerpos anti-fcrh5 e inmunoconjugados y metodos de uso.
DK2500036T3 (da) * 2011-03-18 2014-08-04 Metheresis Translational Res Sa MET-hæmmere til øgning af virkningen af radioterapi
KR20140033029A (ko) * 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
EP2782932A1 (en) * 2011-11-21 2014-10-01 F.Hoffmann-La Roche Ag Purification of anti-c-met antibodies
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
MX2019008538A (es) * 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063816A2 (en) * 2003-12-19 2005-07-14 Genentech, Inc. Monovalent antibody fragments useful as therapeutics
WO2007090807A1 (en) 2006-02-06 2007-08-16 Metheresis Translational Research S.A. Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
WO2013033008A2 (en) * 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
WO2014108829A1 (en) * 2013-01-09 2014-07-17 Metheresis Translational Research S.A. New antibody fragments, compositions and uses thereof

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
"Sequences of proteins of immunological interest", vol. 1, 1991, pages: 688 - 696
ATWELL S; RIDGWAY JB; WELLS JA; CARTER P: "Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library", J MOL BIOL, vol. 270, no. 1, 1997, pages 26 - 35, XP004453749, DOI: doi:10.1006/jmbi.1997.1116
BASILICO C; MODICA C; MAIONE F; VIGNA E; COMOGLIO PM: "Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody- ''decoy'' strategy", INT J CANCER, 25 April 2018 (2018-04-25)
BLOOM JW; MADANAT MS; MARRIOTT D; WONG T; CHAN SY: "Intrachain disulfide bond in the core hinge region of human IgG4", PROTEIN SCI, vol. 6, no. 2, 1997, pages 407 - 415, XP002329379
BORK P; DOERKS T; SPRINGER TA; SNEL B: "Domains in plexins: links to integrins and transcription factors", TRENDS BIOCHEM SCI, vol. 24, no. 7, 1999, pages 261 - 263, XP004171834, DOI: doi:10.1016/S0968-0004(99)01416-4
COMOGLIO PM; TRUSOLINO L; BOCCACCIO C.: "Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy", NAT REV CANCER, vol. 18, no. 6, 2018, pages 341 - 358
FERRACINI R; LONGATI P; NALDINI L; VIGNA E; COMOGLIO PM: "Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase", J BIOL CHEM, vol. 266, no. 29, 1991, pages 19558 - 19564, XP000941367
FOVEAU B; ANCOT F; LEROY C; PETRELLI A; REISS K; VINGTDEUX V ET AL.: "Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis", MOL BIOL CELL, vol. 20, no. 9, 2009, pages 2495 - 2507
G. PACCHIANA ET AL: "Monovalency Unleashes the Full Therapeutic Potential of the DN-30 Anti-Met Antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 46, 12 November 2010 (2010-11-12), pages 36149 - 36157, XP055086806, ISSN: 0021-9258, DOI: 10.1074/jbc.M110.134031 *
GANDINO L; LONGATI P; MEDICO E; PRAT M; COMOGLIO PM: "Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase", J BIOL CHEM, vol. 269, no. 3, 1994, pages 1815 - 1820, XP002906269
GARCIA-DIAZ A; SHIN DS; MORENO BH; SACO J; ESCUIN-ORDINAS H; RODRIGUEZ GA ET AL.: "Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression", CELL REP, vol. 19, no. 6, 2017, pages 1189 - 1201
GHERARDI E; LOVE CA; ESNOUF RM; JONES EY: "The sema domain", CURR OPIN STRUCT BIOL, vol. 14, no. 6, 2004, pages 669 - 678, XP005764679, DOI: doi:10.1016/j.sbi.2004.10.010
HARRIS WJ: "Production of humanized monoclonal antibodies for in vivo imaging and therapy", BIOCHEM SOC TRANS, vol. 23, no. 4, 1995, pages 1035 - 1038
HUMPHREYS DP; CHAPMAN AP; REEKS DG; LANG V; STEPHENS PE: "Formation of dimeric Fabs in Escherichia coli: effect of hinge size and isotype, presence of interchain disulphide bond, Fab' expression levels, tail piece sequences and growth conditions", J IMMUNOL METHODS, vol. 209, no. 2, 1997, pages 193 - 202, XP004103797, DOI: doi:10.1016/S0022-1759(97)00172-5
HURLE MR; GROSS M: "Protein engineering techniques for antibody humanization", CURR OPIN BIOTECHNOL, vol. 5, no. 4, 1994, pages 428 - 433, XP023601527, DOI: doi:10.1016/0958-1669(94)90053-1
JANEWAY ET AL.: "Immuno Biology: the immune system in health and disease", 1999, ELSEVIER SCIENCE LTD.
JONES PT; DEAR PH; FOOTE J; NEUBERGER MS; WINTER G: "Replacing the complementarity-determining regions in a human antibody with those from a mouse", NATURE, vol. 321, no. 6069, 1986, pages 522 - 525
KONG-BELTRAN M; SESHAGIRI S; ZHA J; ZHU W; BHAWE K; MENDOZA N ET AL.: "Somatic mutations lead to an oncogenic deletion of met in lung cancer", CANCER RES, vol. 66, no. 1, 2006, pages 283 - 289, XP002474266, DOI: doi:10.1158/0008-5472.CAN-05-2749
MAKABE K; NAKANISHI T; TSUMOTO K; TANAKA Y; KONDO H; UMETSU M ET AL.: "Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528", J BIOL CHEM, vol. 283, no. 2, 17 October 2007 (2007-10-17), pages 1156 - 1166, XP055110460, DOI: doi:10.1074/jbc.M706190200
MANIATIS T.: "Molecular cloning: A laboratory manual", 1982, COLD SPRING HARBOR LABORATORY
PACCHIANA G; CHIRIACO C; STELLA MC; PETRONZELLI F; DE SANTIS R; GALLUZZO M ET AL.: "Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody", J BIOL CHEM, vol. 285, no. 46, 10 September 2010 (2010-09-10), pages 36149 - 36157
PETRELLI A; GILESTRO GF; LANZARDO S; COMOGLIO PM; MIGONE N; GIORDANO S: "The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met", NATURE, vol. 416, no. 6877, 2002, pages 187 - 190
PONZETTO C; BARDELLI A; ZHEN Z; MAINA F; DALLA ZONCA P; GIORDANO S ET AL.: "A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family", CELL, vol. 77, no. 2, 1994, pages 261 - 271, XP024245267, DOI: doi:10.1016/0092-8674(94)90318-2
PRAT M; CREPALDI T; PENNACCHIETTI S; BUSSOLINO F; COMOGLIO PM: "Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF", J CELL SCI, vol. 111, 1998, pages 237 - 247, XP055561472
PRESTA LG: "Antibody engineering", CURR OPIN BIOTECHNOL, vol. 3, no. 4, 1992, pages 394 - 398, XP023601588, DOI: doi:10.1016/0958-1669(92)90168-I
REGE-CAMBRIN G; SCARAVAGLIO P; CAROZZI F; GIORDANO S; PONZETTO C; COMOGLIO PM ET AL.: "Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene", CANCER GENET CYTOGENET, vol. 64, no. 2, 1992, pages 170 - 173, XP025212176, DOI: doi:10.1016/0165-4608(92)90350-H
REMINGTON, PHARMACEUTICAL SCIENCES, 1980
REMINGTON: "Pharmaceutical Sciences", 1980
RIDGWAY JB; PRESTA LG; CARTER P: "Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization", PROTEIN ENG, vol. 9, no. 7, 1996, pages 617 - 621, XP002610995, DOI: doi:10.1093/protein/9.7.617
RIECHMANN L; CLARK M; WALDMANN H; WINTER G: "Reshaping human antibodies for therapy", NATURE, vol. 332, no. 6162, 1988, pages 323 - 327, XP000020414, DOI: doi:10.1038/332323a0
SCHELTER F; KOBUCH J; MOSS ML; BECHERER JD; COMOGLIO PM ET AL.: "Boccaccio C et al. A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor", J BIOL CHEM, vol. 285, no. 34, 2010, pages 26335 - 26340, XP055389374, DOI: doi:10.1074/jbc.M110.106435
TRUSOLINO L; BERTOTTI A; COMOGLIO PM: "MET signalling: principles and functions in development, organ regeneration and cancer", NAT REV MOL CELL BIOL, vol. 11, no. 12, 2010, pages 834 - 848, XP055087504, DOI: doi:10.1038/nrm3012
VASWANI SK; HAMILTON RG: "Humanized antibodies as potential therapeutic drugs", ANN ALLERGY ASTHMA IMMUNOL, vol. 81, no. 2, 1998, pages 105 - 115, XP026957802
VIGNA E; CHIRIACO C; CIGNETTO S; FONTANI L; BASILICO C; PETRONZELLI F ET AL.: "Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30", MOL ONCOL, vol. 9, no. 9, 2015, pages 1760 - 1772, XP055425203, DOI: doi:10.1016/j.molonc.2015.05.007
WATTS H F ET AL: "Activation of complement pathways by univalent antibody derivatives with intact Fc zones", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 22, no. 7, 1 July 1985 (1985-07-01), pages 803 - 810, XP023852735, ISSN: 0161-5890, [retrieved on 19850701], DOI: 10.1016/0161-5890(85)90146-4 *
ZHU Z; PRESTA LG; ZAPATA G; CARTER P: "Remodeling domain interfaces to enhance heterodimer formation", PROTEIN SCI, vol. 6, no. 4, 1997, pages 781 - 788, XP055345091, DOI: doi:10.1002/pro.5560060404
ZOU W; CHEN L: "Inhibitory B7-family molecules in the tumour microenvironment", NAT REV IMMUNOL, vol. 8, no. 6, 2008, pages 467 - 477, XP009142446, DOI: doi:10.1038/nri2326

Also Published As

Publication number Publication date
EP3864050B1 (en) 2022-11-23
SMT202300053T1 (it) 2023-03-17
ES2938714T3 (es) 2023-04-14
HUE060843T2 (hu) 2023-04-28
EP3864050A1 (en) 2021-08-18
WO2020074459A1 (en) 2020-04-16
SG11202103575RA (en) 2021-05-28
JP7371093B2 (ja) 2023-10-30
DK3864050T3 (da) 2023-02-20
EP4194469A1 (en) 2023-06-14
PL3864050T3 (pl) 2023-04-11
LT3864050T (lt) 2023-03-27
AU2019358417B2 (en) 2025-12-18
FI3864050T3 (fi) 2023-03-14
KR20250078600A (ko) 2025-06-02
AU2026201438A1 (en) 2026-03-19
KR102814490B1 (ko) 2025-06-02
KR20210075121A (ko) 2021-06-22
IL282033A (en) 2021-05-31
JP2022504392A (ja) 2022-01-13
CY1125831T1 (el) 2026-02-25
US20250101115A1 (en) 2025-03-27
US20210395372A1 (en) 2021-12-23
CA3115582A1 (en) 2020-04-16
DK3864050T5 (da) 2024-08-12
CN119587692A (zh) 2025-03-11
RS63960B1 (sr) 2023-02-28
IL282033B2 (en) 2026-02-01
IL282033B1 (en) 2025-10-01
HRP20230154T1 (hr) 2023-03-31
PT3864050T (pt) 2023-01-18
SI3864050T1 (sl) 2023-03-31
CN113330032B (zh) 2025-01-03
AU2019358417A2 (en) 2021-06-24
CN113330032A (zh) 2021-08-31
AU2019358417A1 (en) 2021-05-27
US12209129B2 (en) 2025-01-28

Similar Documents

Publication Publication Date Title
US12162941B2 (en) Anti-CD112R compositions and methods
CN111601826B (zh) 针对tigit的抗体及其变体
JP7267280B2 (ja) Ｔｒｅｍ１を発現する骨髄細胞を無能化させるための組成物および方法
JP2023055871A (ja) 抗ｎｋｇ２ａ抗体を使用した治療計画
ES2835823T3 (es) Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1
TWI731861B (zh) FcRH5之人源化及親和力成熟抗體及使用方法
ES2816624T3 (es) Anticuerpos que se unen a EGFR y ERBB3
KR102845020B1 (ko) Pd-l1에 대한 항체 및 변이체
JP2023508218A (ja) 抗ｏｘ４０抗体およびその使用
TW200948380A (en) Combination of HGF inhibitor and PTEN agonist to treat cancer
AU2026201438A1 (en) Anti-met fab-fc for the treatment of a tumor and/or metastasis
IT201800003875A1 (it) Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
HK40119612A (zh) 用於治疗肿瘤和/或转移的抗met fab-fc
Ghasemi et al. EV20, a Novel Anti–ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo